慢性淋巴细胞白血病患者成熟血液和骨髓祖细胞树突状细胞存在显著表型缺陷
该研究在未经治疗的慢性淋巴细胞白血病(CLL)患者中,发现血液中六种功能不同的树突状细胞(DC)亚群及骨髓中四种DC发育中间体均显著减少,且与Flt3/FL信号通路改变相关;CLL-IPI高危/极高危患者cDC1和pDC低于低危患者,共享DC亚群缺陷者至首次治疗时间更短。
要点
- 未经治疗CLL患者血液中六种DC亚群及骨髓四种DC发育中间体显著减少。
- DC缺陷与Flt3/FL信号通路改变显著相关,支持前体/子代关系。
- CLL-IPI高危/极高危患者cDC1和pDC低于低危患者,DC缺陷者至首次治疗时间更短。
核心结论
- 未经治疗CLL患者存在血液DC亚群和骨髓DC祖细胞的显著缺陷,与Flt3/FL信号通路改变相关,并可能影响治疗决策。
研究设计与样本
- 研究纳入未经治疗的CLL(UT-CLL)患者,检测血液中六种功能不同的DC亚群和骨髓中四种DC发育中间体,并分析其与Flt3/FL信号通路及CLL-IPI的关系。
主要发现
- 未经治疗CLL患者血液中六种功能不同的DC亚群显著减少。
- 未经治疗CLL患者骨髓中四种DC发育中间体显著减少,支持前体/子代关系。
- 血液DC和骨髓DC祖细胞的缺陷与Flt3/FL信号通路改变显著相关。
- CLL-IPI高危/极高危患者cDC1和pDC低于低危患者。
- 共享DC亚群缺陷的未经治疗CLL患者至首次治疗时间更短。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic lymphocytic leukemia (CLL) patients are immunocompromised and highly vulnerable to serious recurrent infections. Conventional dendritic cells (cDCs) and plasmacytoid DCs (pDCs) are principal sensors of pathogen challenge and are essential in orchestrating innate and adaptive immune responses to resolve infection. This study identified significant deficiencies in six functionally distinct DC subsets in blood of untreated CLL (UT-CLL) patients and selective normalization of pDCs in response to acalabrutinib (a Bruton tyrosine kinase inhibitor) therapy. DCs are continuously replenished from hematopoiesis in bone marrow (BM). Four BM developmental intermediates that give rise to cDCs and pDCs were examined and significant reductions identified in UT-CLL patients supporting a precursor/progeny relationship. The deficiencies in blood DCs and BM DC progenitors were significantly associated with alterations in the Flt3/FL signaling pathway critical to DC development and function. The CLL International Prognostic Index (CLL-IPI), a highly accurate model to predict progression-free survival and time-to-first treatment (TTFT), revealed that cDC1 and pDC were reduced in High/Very High CLL-IPI compared to Low CLL-IPI patients. Notably, UT-CLL patients with shared DC subset deficiencies had shorter TTFT, uncovering a profound alteration in innate immunity with the potential to instruct therapeutic decision-making.
引用
- Welch BM, Parikh SA, Kay NE, et al. Profound phenotypic deficiencies in mature blood and bone marrow progenitor dendritic cells in chronic lymphocytic leukemia patients. Leukemia. 2025. PMID: 40571743. doi:10.1038/s41375-025-02579-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。